시장보고서
상품코드
1813859

젖산 모니터링 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Lactate Monitoring Devices Market Size, Share & Trends Analysis Report By Product (Chargeable Lactate Meters), By Application (Sports, Medical), By End Use (Hospitals And Clinics), By Region And Segment Forecasts, 2025 - 2033

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

젖산 모니터링 기기 시장 요약

세계 젖산 모니터링 기기 시장 규모는 2024년에 1억 5,073만 달러로 추정되며 2033년에는 3억 2,588만 달러에 달할 것으로 예상되며 2025년부터 2033년까지 9.05%의 CAGR로 성장할 것으로 예상됩니다.

스포츠 및 헬스케어 분야에서 젖산 수치 모니터링의 이점에 대한 인식 증가, 현장 검사에 대한 수요 증가, 원격 환자 모니터링 및 원격의료의 채택 확대는 시장 성장에 기여하는 주요 요인입니다.

또한, 수술 및 수술 후 모니터링에 대한 사용 확대는 시장 성장을 더욱 촉진할 것으로 예상됩니다. 또한, 재택의료의 도입 증가와 고령화도 시장 성장을 더욱 촉진하는 요인으로 작용하고 있습니다.

젖산 모니터링은 특히 패혈증, 외상, 장기부전 등 중증 환자를 관리할 때 핵심적인 진단 도구가 되고 있습니다. 젖산 수치 상승은 눈에 보이는 임상적 악화가 발생하기 전에도 조직의 저관류와 세포의 산소 부채를 나타내는 초기 생화학적 마커로 널리 알려져 있습니다. 이를 통해 임상의는 빠르게 악화될 위험이 있는 환자를 식별하고, 혈역학 안정화 및 관류 회복을 위한 개입을 적시에 시작할 수 있습니다. 2024년 11월, Sepsis Alliance에 따르면 패혈증은 여전히 미국 병원 내 사망 원인 1위로 병원 내 사망의 35%를 차지합니다.

또한, 젖산 모니터링은 조직 관류 장애가 우려되는 보다 광범위한 질환의 관리에도 필수적입니다. 외상, 심정지, 복잡한 수술 후 장면에서 활력 징후가 변하기 전에 젖산 수치의 상승은 종종 근본적인 순환 장애의 신호가 될 수 있습니다. 임상의들은 이 지표를 사용하여 쇼크의 심각성을 평가하고, 치료의 에스컬레이션을 유도하고, 외과적 개입, 수혈 또는 고급 생명 유지 조치에 대한 결정을 내릴 때 이 지표를 활용합니다.

또한, 젖산 수치의 상승은 불충분한 조직 관류 및 내출혈과 같은 합병증을 나타낼 수 있기 때문에 특히 심장, 복부, 외상 등 주요 수술 중 및 수술 후 젖산 모니터링이 많이 채택되고 있습니다. 수술 중 모니터링은 마취과 의사와 외과 의사가 적시에 임상적 판단을 내릴 수 있게 하고, 수술 후 모니터링은 유해한 결과를 조기에 발견할 수 있도록 지원하며, 궁극적으로 회복률을 향상시킵니다.

예를 들어, 2025년 1월 Journal of Clinical Medicine에 게재된 '저체온 산소 기계관류에서 간 이식편 품질의 실시간 바이오마커'라는 제목의 연구에서는 이식 전 간 이식편의 품질을 평가하는 실시간 접근 가능한 바이오마커로서 이중 저체온 산소 기계관류(dHOPE) 중 관류액 젖산 농도의 활용이 검토되었습니다. 이 조사에서는 dHOPE 120분 후 측정한 젖산 수치가 조기 이식편 기능부전(EAD)을 확실하게 예측하고, 이식 후 합병증 및 입원 기간과 상관관계가 있는 것으로 나타났습니다. 이 접근법은 복잡한 바이오마커 분석에 대한 비용 효율적이고 반복 가능한 대안을 제공하고 장기 이용과 환자 예후를 개선하기 위해 이식 센터 전반에 걸쳐 젖산 모니터링을 광범위하게 채택할 것을 제안합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 젖산 모니터링 기기 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련/보조적인 시장 전망.
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 젖산 모니터링 기기 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
  • 의료 용도용 젖산 모니터링 기기 임상시험

제4장 젖산 모니터링 기기 시장 : 제품 추정·동향 분석

  • 부문 대시보드
  • 세계의 젖산 모니터링 기기 시장 제품 변동 분석
  • 젖산 모니터링 기기 시장 규모와 동향 분석(제품별, 2021-2033년)
  • 충전식 젖산 측정기
  • 배터리식 젖산 측정기

제5장 젖산 모니터링 기기 시장 : 용도 추정·동향 분석

  • 부문 대시보드
  • 세계의 젖산 모니터링 기기 시장 용도 변동 분석
  • 젖산 모니터링 기기 시장 규모와 동향 분석(용도별, 2021-2033년)
  • 스포츠
  • 의료
  • 기타

제6장 젖산 모니터링 기기 시장 : 최종 용도 추정·동향 분석

  • 부문 대시보드
  • 세계의 젖산 모니터링 기기 시장 최종 용도 변동 분석
  • 젖산 모니터링 기기 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
  • 병원과 진료소
  • 스포츠 연구소
  • 홈케어
  • 기타

제7장 젖산 모니터링 기기 시장 : 지역 추정·동향 분석

  • 지역별 시장 점유율 분석, 2024년 및 2033년
  • 지역 시장 대시보드
  • 시장 규모와 예측 동향 분석, 2021년에서 2033년 :
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
    • 뉴질랜드
    • 싱가포르
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트
    • 카타르

제8장 경쟁 구도

  • 기업/경쟁 분류
  • 전략 매핑
  • 기업 시장 상황 분석, 2024년
  • 기업 개요/상장 기업
    • Nova Biomedical
    • ARKRAY, Inc.
    • EKF Diagnostics
    • TECOM Analytical Systems
    • Sensa Core Medical
    • VivaCheck Biotech
    • ApexBio
    • TaiDoc Technology Corporation
KSM 25.09.26

Lactate Monitoring Devices Market Summary

The global lactate monitoring devices market size was estimated at USD 150.73 million in 2024 and is projected to reach USD 325.88 million by 2033, growing at a CAGR of 9.05% from 2025 to 2033. The increasing awareness of the benefits of monitoring lactate in sports & healthcare, the rise in the need for point-of-care tests, and the growing adoption of remote patient monitoring & telemedicine are significant factors contributing to market growth.

In addition, expanding use in surgical and post-operative monitoring is further anticipated to propel market growth. Moreover, an increase in the adoption of home-based healthcare and the aging population are some other factors fueling market growth further.

Lactate monitoring has become a core diagnostic tool in managing critically ill patients, particularly in the context of sepsis, trauma, and organ dysfunction. Elevated lactate levels are widely recognized as an early biochemical marker of tissue hypoperfusion and cellular oxygen debt, even before visible clinical deterioration occurs. This allows clinicians to identify patients at risk of rapid decline and initiate timely interventions aimed at stabilizing hemodynamics and restoring perfusion. In November 2024, according to Sepsis Alliance, sepsis remained the leading cause of death in U.S. hospitals, accounting for 35% of in-hospital deaths.

Moreover, lactate monitoring is also critical in managing a broader range of conditions where impaired tissue perfusion is a concern. In trauma, cardiac arrest, and complex post-surgical scenarios, elevated lactate levels often signal underlying circulatory compromise before vital signs shift. Clinicians rely on this metric to assess the severity of shock, guide escalation of care, and support decisions around surgical intervention, transfusion, or advanced life support.

Furthermore, lactate monitoring is increasingly being adopted during and after major surgeries, particularly cardiac, abdominal, and trauma procedures, as elevated lactate levels can indicate insufficient tissue perfusion or complications such as internal bleeding. Intraoperative monitoring enables anesthesiologists and surgeons to make timely clinical decisions, while post-operative monitoring supports early identification of adverse outcomes, ultimately improving recovery rates.

For instance, a study titled "Real-Time Biomarkers of Liver Graft Quality in Hypothermic Oxygenated Machine Perfusion," published in the Journal of Clinical Medicine in January 2025, explored the use of perfusate lactate concentration during dual hypothermic oxygenated machine perfusion (dHOPE) as a real-time, accessible biomarker to assess liver graft quality pre-transplantation. The study demonstrated that lactate levels measured after 120 minutes of dHOPE reliably predicted early allograft dysfunction (EAD) and correlated with post-transplant complications and length of hospital stay. This approach offers a cost-effective and reproducible alternative to complex biomarker assays, advocating for the broader adoption of lactate monitoring across transplant centers to improve organ utilization and patient outcomes.

Global Lactate Monitoring Devices Market Report Segmentation

This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lactate monitoring devices market report based on product, application, end use, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Chargeable Lactate Meters
  • Battery Operated Lactate Meters
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Sports
  • Medical
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Clinics
  • Sports Institutes
  • Home Care
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
    • New Zealand
    • Singapore
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Lactate Monitoring Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of sepsis and critical illnesses
      • 3.2.1.2. Growing use in sports and fitness performance
      • 3.2.1.3. Advancements in point-of-care and wearable technologies
      • 3.2.1.4. Expanding use in surgical and post operative monitoring
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited penetration in low-resource healthcare settings
      • 3.2.2.2. Clinical reliance on broader blood gas panels
  • 3.3. Lactate Monitoring Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
      • 3.3.2.6. Social Landscape
  • 3.4. Clinical Trials of Lactate Monitoring Devices for Medical Application

Chapter 4. Lactate Monitoring Devices Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Lactate Monitoring Devices Market Product Movement Analysis
  • 4.3. Global Lactate Monitoring Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Chargeable Lactate Meters
    • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Battery Operated Lactate Meters
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Lactate Monitoring Devices Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Lactate Monitoring Devices Market Application Movement Analysis
  • 5.3. Global Lactate Monitoring Devices Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Sports
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Medical
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Lactate Monitoring Devices Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Lactate Monitoring Devices Market End Use Movement Analysis
  • 6.3. Global Lactate Monitoring Devices Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Hospitals & Clinics
    • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. Sports Institutes
    • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Home Care
    • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Lactate Monitoring Devices Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.7. New Zealand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. New Zealand market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.8. Singapore
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Singapore market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.5. Qatar
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Regulatory framework
      • 7.8.5.3. Competitive scenario
      • 7.8.5.4. Qatar market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Nova Biomedical
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. ARKRAY, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. EKF Diagnostics
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. TECOM Analytical Systems
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Sensa Core Medical
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. VivaCheck Biotech
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. ApexBio
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. TaiDoc Technology Corporation
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiativesList of Tables
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제